UrgoStart Plus Border is now available in new shapes and sizes!
Evidence-based treatment should be for every body, which is why we are pleased to announce that UrgoStart Plus Border now comes in a variety of new shapes, including 10x12cm, 13x13cm, and 17x20cm.
These new anatomical shapes are designed to fit complex body locations and make wound care easier – ensuring that every patient can be treated with a dressing that is right for them and their wound.2,3
UrgoStart Plus is suitable for patients with risk factors*, including diabetes, vascular factors, reduced mobility, older age and more.
*unless there is a known sensitivity or contraindication – see product leaflet for details
References:
1. National Institute for Health and Care Excellence (NICE), UrgoStart for treating leg ulcers and diabetic foot ulcers, https://www.nice. org.uk/guidance/
mtg42, April 2023
2. URGO RID Panel tests with nurses, conducted March 2024
3. Versus standard formats, Quantitative test UrgoStart Plus border study report No.22009-2- March 2022
4. Internal in vitro study, Laboratoires Urgo
5. Münter KC, et al. The reality of routine practice: a pooled data analysis on chronic wounds treated with TLC-NOSF wound dressings. J Wound Care.
2017;26(Suppl 2):S4–S15. doi:10.12968/jowc.2017.26.Sup2.S4
6. Edmonds M, et al. Sucrose octasulfate dressing versus control dressing in patients with neuroischaemic diabetic foot ulcers (Explorer): an international,
multicentre, double-blind, randomised, controlled trial. Lancet Diabetes Endocrinol. 2018;6(3):186–96. https://doi.org/10.1016/S2213-8587(17)30492-2
7. Meaume S, et al. Evaluation of two fibrous wound dressings for the management of leg ulcers: results of a European randomised controlled trial (EARTH
RCT). J Wound Care. 2014;23(3):105–16. https://doi.org/10.12968/jowc.2014.23.3.105
8. Sigal ML, et al. Clinical evaluation of a new TLC-NOSF dressing with poly-absorbent fibers for the local management of exuding leg ulcers, at the
different stages of the healing process: Results from two multicentric, single-arm, prospective, open-label clinical trials. J Wound Care. 2019;28(3):164–75.